Robotic Hysterectomy: Procedures Increasing, But Questions Remain

Controversy continues to swirl around robotic surgical procedures and this time the target is robotic hysterectomy. However, the drama does not seem to be impacting the number of these procedures performed robotically, a statistic that is clearly on the rise.

The US has the highest rate of hysterectomy in the industrialized world, and according to the Centers for Disease Control & Prevention, it is the second most frequently performed surgical procedure in women (after Cesarean section). Approximately 600,000 hysterectomies are performed annually in the US, with the vast majority for noncancerous conditions such as menorrhagia. The total number of procedures has been on a gradual decline over the last several years; however, the number of cases performed minimally invasively and robotically is going up. Robotic-assisted hysterectomy using the only US Food and Drug Administration-approved system, the da Vinci Surgical System from Intuitive Surgical Inc., was performed in approximately 176,000 patients in 2012, up from about 140,000 cases in 2011, according to the company. However, controversies persist with robotic technology, and the results of a new study cite the potential higher costs of robotics.

According to the results of a large cohort study published February 20 in the Journal of the American Medical Association, while da Vinci hysterectomy (dVH) clinical results are equivalent to...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

More from Medtech Insight

Execs On The Move: 5-9 May 2025

 
• By 

An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.

TRiCares Tricuspid Valve Replacement System Reduces Regurgitation In First-In-Human Study

 

TRiCares presented data from the first-in-human study for its tricuspid valve replacement system – Topaz – at EuroPCR 2025 on 22 May.

Swiss Medtechs Advised To Work On US Tariff Mitigation Strategies

 
• By 

The US’ 90-day suspension of higher “reciprocal tariffs” will expire on 9 July, raising fears that the 31% tariff rate on Swiss medtech and other goods exported to the US might make a comeback. While the tariff situation changes on an almost daily basis, medtechs should forearm for any eventually, say local business organizations.